Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIEGE trial of nab-paclitaxel plus gemcitabine scheduling in metastatic pancreatic cancer
2013-001868-40Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Dec 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-001868-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001868-40.